Skip to main content
. 2021 Apr 18;7(2):130–138. doi: 10.3390/tomography7020012

Table 4.

Iron chelation therapy and volume of red cell transfusion of thalassemia patients with and without cardiac siderosis.

Patients with Cardiac Siderosis (n = 21) Patients without Cardiac Siderosis (n = 98) p-Value
Iron chelation therapy

  • DFO, n (%)

 11 (52.4) 28 (28.6) 0.36

  • DFX, n (%)

 4 (19) 20 (20.4) 0.89

  • DFP, n (%)

 2 (9.6) 49 (50) 0.0007 *
Combination therapy, n (%) 4 (19) 1 (1) 0.0002 *
Volume of red cell transfusion (unit/year) 19.6 ± 6.9 11.1 ± 7.8 <0.0001 *

DFO: Desferrioxamine, DFX: Deferasirox, DFP: Deferiprone; * Statistically significant at p-value < 0.05.